Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma
Yuxuan CheYang LiuYijing LiJoseph McIntoshAlexa A JordanFangfang YanWei WangLei NieHeng‐Huan LeeJingling JinYixin YaoZhongming ZhaoChangying JiangMichael Wang
3
Citation
14
Reference
10
Related Paper
Citation Trend
Mantle cell lymphoma is a rare subtype of non-Hodgkin’s lymphoma with poor prognosis and continue to be challenging to treat. The choice of first line induction regimen remains a topic of debate due paucity of clinical trials. We retrospectively evaluated 66 patients diagnosed with mantle cell lymphoma who achieved first complete response after induction chemotherapy followed by autologous stem cell transplant. Treatment groups were divided into low-intensity versus high-intensity regimens. Our data showed the intensity of induction regimen does not impact posttransplant outcomes of mantle cell lymphoma who underwent autologous stem cell transplant in first complete response.
Autologous stem-cell transplantation
Cite
Citations (1)
Cite
Citations (21)
Abstract Primary testicular non‐Hodgkin lymphoma ( NHL ) is a rare entity with the most common histologic subtype consisting of diffuse large B‐cell lymphoma ( DLBCL ). Patients with primary testicular lymphoma ( PTL ) have a poor prognosis and a higher propensity for relapse. Also rare are composite lymphomas ( CL ) defined as two or more morphologically and phenotypically distinct lymphomas coexisting in a single organ or tissue. Here we present the first reported case of primary testicular composite lymphoma consisting of DLBCL and mantle cell lymphoma ( MCL ).
Cite
Citations (8)
Mantle-cell lymphoma is a lymphoma subtype characterized by the overexpression of cyclin D1 and the dysregulation of the cell cycle. Many secondary genetic events contribute to growth in mantle-cell lymphoma, including the loss of DNA damage-response capacity, the activation of cell-survival pathways, and the inhibition of apoptosis.1,2 The prognosis in mantle-cell lymphoma is the worst among B-cell lymphomas. Remissions achieved with conventional chemotherapy are often short-lived, and very intensive regimens, including stem-cell transplantation, seem necessary to improve the outcome, but they are feasible in only a limited number of patients.3 Ibrutinib (PCI-32765) is an orally active irreversible inhibitor of . . .
Cite
Citations (20)
Hematology
Autologous stem-cell transplantation
Cite
Citations (78)
Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma. The MCL is classified into two subtypes, some patients have a chronic/indolent course and the others have a more aggressive course and short survival. In recent years, some novel therapeutic target agents for MCL have reports. These target agents achieve efficacy comparable to conventional chemotherapy in relapsed/refractory MCL. Therapeutic targents for MCL include the surface antigens of B-cell lymphoma, B-cell receptor signaling, DNA damage response pathway and the cellular microenviroment. This review focused on the recent research progress of target agents in the treatment of MCL.
Key words:
Lymphoma, mantle cell; Target agent
Aggressive lymphoma
Cite
Citations (0)
Autologous stem-cell transplantation
Cite
Citations (3)
Immunophenotyping
Hematology
IGHV@
Cite
Citations (2)
Manifestations of mantle cell lymphoma were recognized in the 1970s as distinct from those associated with the more readily classifiable lymphomas. It was not until the 1990s, however, that observation of a combination of immunologic, cytogenetic, and molecular genetic abnormalities characteristic of this new malignancy confirmed its existence. The clinical and pathologic entity was named mantle cell lymphoma and in 1994 was incorporated into the Revised European American Lymphoma Classification. Mantle cell lymphoma is a CD5 positive, B-cell lymphoma that usually displays the t(11;14). The lymphoma has a striking male predominance and is widely disseminated at diagnosis in 80% of patients. Mantle cell lymphoma responds poorly to available therapies, and the median survival is approximately 3 years.
CD5
Cite
Citations (19)
Východiska: Lymfom z plášťových buněk představuje specifi cký podtyp B-non-Hodgkinova lymfomu charakterizovaný na molekulární úrovni přítomností translokace t(11;14)(q13;q32), která vede k aberantní expresi cyklinu D 1 a následné deregulaci buněčného cyklu.Navzdory sporadickému výskytu indolentních forem lymfomu z plášťových buněk nevyžadujících řadu měsíců či dokonce let terapii převažují v běžné klinické praxi jednoznačně agresivní formy lymfomu z plášťových buněk.Přestože má lymfom z plášťových buněk chemosenzitivní povahu, cca 10 % pa cientů na léčbu neodpoví (refrakterní nemoc) a většina zbylých pa cientů prodělá dříve či později návrat (relaps) choroby.Průběh léčby lymfomu z plášťových buněk tak z dlouhodobé perspektivy obvykle probíhá pod obrazem chronicky relabujícího onemocnění vyžadujícího aplikace dalších a dalších linií léčby.Prognóza relabujícího lymfomu z plášťových buněk je však extrémně nepříznivá.Cíl: Cílem tohoto přehledu je shrnout současné postupy v dia gnostice a terapii lymfomu z plášťových buněk.Výsledky: Terapeutický algoritmus
Cite
Citations (0)